1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,240 | 0,281 | 13:05 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | QLife Holding AB: Egoo Health achieves breakthrough precision in key diabetes biomarker test, paving the way for partnerships | 64 | GlobeNewswire (Europe) | Qlife Holding AB ("Qlife" or the "Company"), a pioneer in clinical-grade home diagnostics, together with its partner Hipro Biotechnology Co., Ltd. ("Hipro"), announces a major milestone: the Egoo HbA1c... ► Artikel lesen | |
| QLIFE Aktie jetzt für 0€ handeln | |||||
| 23.12.25 | QLife Holding AB: Qlife provides end-year operational update on key issues | 461 | GlobeNewswire (Europe) | Qlife Holding AB ("Qlife" or the "Company"), a pioneer in clinical-grade home diagnostics, provides a year-end operational update on key issues.
Diabetes data
Egoo Health has achieved breakthrough... ► Artikel lesen | |
| 16.12.25 | QLife Holding AB: Qlife and Hipro sign exclusive commercial agreement covering Qlife's sale of Hipro products in EU and US markets | 131 | GlobeNewswire (Europe) | Qlife Holding AB ("Qlife" or the "Company"), a first mover in clinical-grade home diagnostics, today announced that it has entered into an exclusive commercial agreement with Hipro Biotechnology Co.... ► Artikel lesen | |
| 16.12.25 | QLife Holding AB: The Letter of Intent with Hipro Biotechnology regarding the reverse takeover has been extended until 31 December 2026 and the valuation term will re-evaluated once a structure has been established | 214 | GlobeNewswire (Europe) | Qlife Holding AB ("Qlife" or the "Company") announces an extension of the non-binding Letter of Intent regarding the potential reverse takeover (the "Transaction") with Hipro Biotechnology Co., Ltd.... ► Artikel lesen | |
| 12.12.25 | QLife Holding AB: Egoo Health powers AI-driven personalized diabetes management in China | 186 | GlobeNewswire (Europe) | Qlife Holding AB ("Qlife" or the "Company") is proud to announce that its Egoo Health blood testing platform will play a central role in a groundbreaking project launched by Hipro Biotechnology Co.... ► Artikel lesen | |
| 05.12.25 | QLife Holding AB: Qlife's Birmingham PKU clinical trial published with strong results - key milestone toward CE-mark submission and market launch | 124 | GlobeNewswire (Europe) | Qlife Holding AB ("Qlife" or the "Company") a first mover in clinical-grade home diagnostics, announces publication of the clinical study for PKU children and adolescents under 18 years of age. The... ► Artikel lesen | |
| 14.11.25 | QLife Holding AB: Update on the reverse takeover process - "Red Chip" structure will not be approved by Nasdaq - other structures are pursued | 236 | GlobeNewswire (Europe) | Qlife Holding AB ("Qlife" or "the Company") and Hipro Biotechnology Co., Ltd. ("Hipro") are working on the planned reverse takeover, as announced in press releases on 5 June 2025 and 5 October 2025.... ► Artikel lesen | |
| 12.11.25 | Qlife Holding AB Q3 Sales Decline | 1 | RTTNews | ||
| 12.11.25 | QLife Holding AB: QLIFE HOLDING AB, Interim Report Q3, July - September 2025 | 129 | GlobeNewswire (Europe) | Advancing Integration & Innovation: Building a Diagnostics Powerhouse
The full report is attached and can also be found here: https://qlifeholding.com/en/investors/finansiella-rapporter
Financial summary... ► Artikel lesen | |
| 05.10.25 | QLife Holding AB: The Letter of Intent with Hipro Biotechnology Co., Ltd. regarding reverse takeover has been extended | 100 | GlobeNewswire (Europe) | Qlife Holding AB ("Qlife" or the "Company") announces an extension of the Letter of Intent regarding a potential reverse takeover (the "Transaction") with Hipro Biotechnology Co., Ltd. ("Hipro"). The... ► Artikel lesen | |
| 22.09.25 | Qlife Holding AB announces the outcome of the exercise of warrants series TO 6 | 1 | Cision News | ||
| 15.09.25 | QLife Holding AB: Qlife announces additional product line and progresses two new tests into clinical trials | 155 | GlobeNewswire (Europe) | Qlife, a first mover in clinical-grade home diagnostics, and its partner Hipro Biotechnology are advancing two additional biomarker tests-nt-proBNP and potassium-into clinical trials targeting Congestive... ► Artikel lesen | |
| 27.08.25 | QLife Holding AB: QLIFE HOLDING AB, Interim Report Q2, April to June 2025 | 239 | GlobeNewswire (Europe) | Towards a merger with a vision
The full report is attached and can also be found here: https://qlifeholding.com/en/investors/finansiella-rapporter
Financial summary - second quarter 2025
Revenue... ► Artikel lesen | |
| 27.08.25 | QLife Holding AB: Progress update on the reverse takeover process between Qlife and Hipro | 184 | GlobeNewswire (Europe) | Gothenburg, Sweden - Qlife Holding AB ("Qlife" or the "Company") and Hipro Biotechnology Co., Ltd. ("Hipro") remain fully committed to completing the transaction announced in the Letter of Intent signed... ► Artikel lesen | |
| 21.08.25 | Qlife Holding AB increases existing credit facility and extends the maturity date | 1 | Cision News | ||
| 21.08.25 | QLIFE HOLDING AB: Qlife together with Birmingham Women's and Children's NHS Foundation Trust achieve positive results for its rare disease self-test PHE product | 2 | Cision News | ||
| 05.06.25 | Qlife Holding AB receives observation status | 265 | GlobeNewswire | Today, June 5, 2025, Qlife Holding AB (the "Company") issued a press release with information that it has entered into a letter of intent for a reverse takeover of Hipro Biotechnology Co., Ltd.,... ► Artikel lesen | |
| 05.06.25 | QLife Holding AB: Qlife enters letter of intent with Hipro Biotechnology Co., Ltd. to join forces through a reverse takeover | 273 | GlobeNewswire (Europe) | Qlife Holding AB ("Qlife" or the "Company") has entered into a non-binding letter of intent ("Letter of Intent") with Hipro Biotechnology Co., Ltd., registration no. 91130100794182204D, ("Hipro") regarding... ► Artikel lesen | |
| 28.05.25 | QLife Holding AB: Bulletin from the annual general meeting 2025 of Qlife Holding AB | 190 | GlobeNewswire (Europe) | Qlife Holding AB held its annual general meeting on 28 May 2025. At the meeting, the following resolutions were made.
The English text is an unofficial translation. In case of any discrepancies between... ► Artikel lesen | |
| 20.05.25 | QLife Holding AB: QLIFE HOLDING AB, Interim Report Q1, January to March 2025 | 367 | GlobeNewswire (Europe) | Progress on all levels
The full report is attached and can also be found here: https://qlifeholding.com/en/investors/finansiella-rapporter
Financial summary - first quarter 2025
Revenue in the... ► Artikel lesen |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MOUNTAIN VALLEY MD | 0,007 | 0,00 % | Mountain Valley MD Holdings Inc: Mountain Valley appoints Batchelor as director | ||
| VENUS CONCEPT | 7,940 | +455,24 % | Venus Concept Stock Explodes Over 500% After Major Investor Takes Control | ||
| FRESENIUS MEDICAL CARE | 37,470 | +1,88 % | Fresenius Medical Care: Aktie wird jetzt zum Kauf empfohlen | Fresenius Medical Care hat in der vergangenen Woche eine Beschleunigung der Aktivitäten beim Rückkauf eigener Aktien angekündigt. Die Analysten von mwb research nutzen dies zu einer Hochstufung des... ► Artikel lesen | |
| FRESENIUS | 49,830 | +0,36 % | Aktien Frankfurt: Dax setzt Rekordrally mit kleinem Schrittchen fort | FRANKFURT (dpa-AFX) - Der Dax hat am Montag nach einem zunächst stabilen Börsenauftakt an seinen zum Jahresbeginn wieder aufgenommenen Rekordlauf angeknüpft. Um die Mittagszeit legte der deutsche Leitindex... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 22,500 | 0,00 % | Alignment Healthcare Reports 31% Year-Over-Year Membership Growth to 275,300 as of Jan. 1, 2026 | Guides year-end 2026 health plan membership range of 290,000 to 296,000. Announces its expectation that consensus adjusted EBITDA of approximately $145 million in 2026 will be within its full-year... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 46,300 | -1,07 % | BERNSTEIN RESEARCH stuft Siemens Healthineers auf 'Outperform' | NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat die Einstufung für Siemens Healthineers auf "Outperform" mit einem Kursziel von 52,90 Euro belassen. 2025 sei ein schlechtes Jahr... ► Artikel lesen | |
| GENEDX | 108,08 | -1,10 % | Sema4.ai: Interview With Co-Founder & CEO Rob Bearden About The Enterprise AI Agent Platform | ||
| BRIGHTSPRING HEALTH SERVICES | 39,200 | -1,01 % | S&P Dow Jones Indices: BrightSpring Health Services Set to Join S&P SmallCap 600 | NEW YORK, Oct. 14, 2025 /PRNewswire/ -- BrightSpring Health Services Inc. (NASD: BTSG) will replace Veritex Holdings Inc. (NASD: VBTX) in the S&P SmallCap 600 effective... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 30,380 | -0,39 % | PROCEPT BioRobotics Reports Third Quarter 2025 Financial Results and Issues 2026 Revenue Guidance | SAN JOSE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen | |
| PROGYNY | 24,520 | +0,86 % | Progyny, Inc. - 8-K, Current Report | ||
| HEARTFLOW | 37,160 | +2,88 % | Heartflow, Inc. - 8-K, Current Report | ||
| BETA BIONICS | 18,500 | +3,99 % | Beta Bionics, Inc.: Beta Bionics to Announce Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026 | ||
| DRAEGERWERK | 89,70 | +11,71 % | Draegerwerk AG & Co. KGaA: Fokus auf die Bewertung: Kursziel erreicht. Von KAUFEN auf HALTEN. | Die Aktien von Drägerwerk (Dräger) sind seit Beginn des Jahres 2026 um nahezu 10% gestiegen, was den Kurs der Aktie nahe an unser Kursziel von 76,00 EUR bringt und eine Herabstufung von "Kaufen" auf... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 39,440 | -0,55 % | BERNSTEIN RESEARCH stuft CARL ZEISS MEDITEC AG auf 'Outperform' | NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat die Einstufung für Carl Zeiss Meditec auf "Outperform" mit einem Kursziel von 50,55 Euro belassen. 2025 sei ein schlechtes Jahr... ► Artikel lesen | |
| BILLIONTOONE | 88,73 | -6,32 % | BillionToOne, Inc.: BillionToOne Provides Guidance for 2026 | MENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are... ► Artikel lesen |
QLIFE HOLDING AB gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 0,216 Euro und damit +22,03 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu QLIFE HOLDING AB finden Sie auf Wallstreet Online.